Follow

BioStock: Coegin Pharma takes key steps for growth during Q3

30 November 2021 - 09:03

Q3 was an active quarter for Coegin Pharma and its pursuit to address a large unmet medical need in cancer and chronic inflammatory diseases. Highlighted in the company’s interim report are the initiation of the COAK study with AVX001 gel in actinic keratosis patients, the merger with Swedish biotech Follicum, and the development of a new candidate for the treatment of leukaemia and potentially other cancers.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/11/coegin-pharma-takes-key-steps-for-growth-during-q3/

This is a press release from BioStock - Connecting Innovation & Capitalhttps://www.biostock.se/

Provided by: Cision
NGM Nordic SME (Sweden)
Coegin Pharma AB
Coegin Pharma specializes in molecular therapy which is further used in therapeutic treatments. Examples of diseases for which the company's solutions are used include cancer, leukemia and chronic kidney disease....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More